Type Public limited company Products Pharmaceuticals Headquarters India | Industry Pharmaceuticals Website www.marksanspharma.com Founded 1992 | |
 | ||
Traded as BSE: 524404
NSE: MARKSANS Key people Mark Saldanha (Managing Director & CEO) Stock price MARKSANS (NSE) ₹ 48.40 -1.00 (-2.02%)10 Mar, 3:30 PM IST - Disclaimer Subsidiaries Marksans Pharma Inc., Relonchem Limited | ||
Marksans Pharma (BSE: 524404, NSE: MARKSANS), headquartered in Mumbai, India, is actively engaged in R&D together with providing CRAMS to international pharmaceutical organizations. The company deals in OTC & prescription drugs which have wide ranging applications crosswise the fields such as Antibiotics, Oncology, Antidiabetic, Gastroenterology, Pain Management, Gynaecology, Cardiovascular, and among others.
Contents
- Restricted gmp status will continue until uk mhra s next inspection marksans pharma
- History
- Mergers and acquisitions
- References
The R&D capabilities of the company involve chemical synthesis, dossier development, formulation development, analytical development, process optimization and conducting stability studies. The corporation owns capabilities from Lab scale development to Pilot scale up also from commercializing the product for manufacturing on large scale to marketing internationally.
Restricted gmp status will continue until uk mhra s next inspection marksans pharma
History
The company was incorporated by Mark Saldanha in 2001. The organization so far has established manufacturing facilities. These plants are approved by UK MHRA, USFDA, Australian TGA and other foreign health authorities.
Mergers and acquisitions
2005: Nova Australasia Pty Ltd., an Australian marketing company which specializes in pharmaceutical products and marketing OTC, was acquired by Marksans in 2005.
2008: UK's Hale Group together with its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell) which manufactures a range of licensed or unlicensed pharmaceutical products, was acquired in 2008.
2008: Relonchem Ltd. , engaged in licensing, marketing and distribution of generic pharmaceutical products to retailers, wholesalers and hospitals in the UK, was acquired in August 2008 by Marksans.